Morphogenesis is a clinical stage company developing novel cell and gene therapies based on distinct and synergistic technology platforms. Our mission is to change the way chronic diseases are treated by engaging the innate intelligence of the body.
While traditional cancer treatments such as surgery, chemotherapy, and radiation are currently important components of cancer treatment, immuno-oncology therapies will soon be the most widely chosen cancer control option.
Morphogenesis Inc.’s leadership in the companion animal cancer treatment market is spearheaded by our wholly-owned subsidiary, Veterinary Oncology Services (VOS). VOS has assisted veterinary oncology physicians nationwide with providing customized treatment for more than 45 different types of cancers in dogs, cats, and horses.